COVID-19 drug discovery and treatment options
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and …
Type‐II IFN inhibits SARS‐CoV‐2 replication in human lung epithelial cells and ex vivo human lung tissues through indoleamine 2, 3‐dioxygenase‐mediated …
Interferons (IFNs) are critical for immune defense against pathogens. While type‐I and‐III
IFNs have been reported to inhibit SARS‐CoV‐2 replication, the antiviral effect and …
IFNs have been reported to inhibit SARS‐CoV‐2 replication, the antiviral effect and …
Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection
L Yu, Y Wang, Y Liu, X Xing, C Li, X Wang, J Shi, W Ma… - bioRxiv, 2024 - biorxiv.org
Monoclonal antibody (mAb) therapeutics hold promise for both preventing and treating
infectious diseases, especially among vulnerable populations. However, the emergence of …
infectious diseases, especially among vulnerable populations. However, the emergence of …
Development of a Multi-Target Pharmacophore-Based Virtual Screening Agent Against COVID-19
NA Ibrahim, AM Gouda… - Al-Mustaqbal Journal of …, 2024 - mjpms.uomus.edu.iq
The worldwide outbreak of the COVID-19 pandemic compelled scientists to develop new,
highly effective therapeutic approaches to fight it. Multitarget drugs have been proven to be …
highly effective therapeutic approaches to fight it. Multitarget drugs have been proven to be …